Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States

CONCLUSIONS: Co-testing is now well established in women aged 30-64 years, but smaller increases have also been seen at younger ages, although this is not currently recommended. The impact of co-testing on cervical disease outcomes and number of colposcopies and biopsies in routine population settings remain important, especially in young women.PMID:34253387 | DOI:10.1016/j.ygyno.2021.06.029

Source: Gynecologic Oncology - July 13, 2021 Category: Cancer & Oncology Authors: Jack Cuzick Ruofei Du Rachael Adcock Walter Kinney Nancy Joste Ruth M McDonald Kevin English Salina M Torres Debbie Saslow Cosette M Wheeler New Mexico HPV Pap Registry Steering Committee Source Type: research